Summary of GeneDx Holdings Corp. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 Revenues: $121 million, a 27% increase year-over-year.

Full-Year Revenues: $428 million, driven by a 54% growth in exome and genome revenues.

Exome and Genome Revenues: $104 million in Q4, up 32% year-over-year; organic growth rate was 42% after excluding a one-time recovery from the previous year.

Volume: 27,761 exome and genome tests reported in Q4, with growth accelerating from 24% in Q1 to 34% by Q4.

Adjusted Net Income: $4.4 million for Q4, $4.8 million for the full year.

Adjusted Gross Margin: 71% for Q4, up from 65% in 2024.

2Strategic Updates and Business Highlights

Market Leadership: GeneDx maintains a leading position in rare disease diagnostics, leveraging its extensive INFINITY dataset, which includes over 2.5 million tests and diverse genetic data.

FDA Breakthrough Device Designation: This positions GeneDx to be the first FDA-authorized comprehensive genomic solution, enhancing its competitive edge.

Sales Force Expansion: Nearly tripling its sales team from approximately 50 to 150 to capture growth in new markets, including general pediatrics and NICU.

New Product Launches: Introduction of a one-minute ordering experience for clinicians, set to launch in mid-2026, aimed at enhancing user experience and increasing test volumes.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected total revenues between $540 million and $555 million, with exome and genome volume growth projected at 33% to 35%.

Market Contributions: Foundational markets (geneticists and pediatric specialists) expected to contribute 25%-27% to growth, while expansion markets (NICU, general pediatrics, and prenatal) are anticipated to contribute 7%-8%.

Adjusted Gross Margin: Expected to remain around 70% for the year, factoring in mix shift dynamics.

4Challenges and Points of Concern

Seasonal Volume Decline: Q1 typically experiences lower volumes due to deductible resets and weather impacts, with expectations of a 33% growth baseline for Q1.

Reimbursement Risks: New markets may face initial high denial rates as payers adjust to new diagnosis codes, which could affect revenue collection.

Competitive Pressures: While GeneDx leads the market, the entry of new competitors could challenge its position, necessitating continued investment in sales and marketing to maintain market share.

5Notable Q&A Insights

Guidance Confidence: Management expressed confidence in their growth assumptions, citing significant white space in clinician activation and conversion from single/multi-gene panels to exome/genome testing.

NICU Market Strategy: The new approach focuses on direct engagement with neonatologists, leveraging insights from a new Chief Medical Officer to enhance adoption rates.

EMR Strategy: GeneDx is shifting its focus on EMR partnerships to target new customers, particularly in the pediatrician market, rather than relying on existing customer unlocks.

Long-Term Vision: Management emphasized the inevitability of exome/genome testing becoming the standard for hereditary disease diagnosis, indicating a strong belief in the market's growth potential. This summary encapsulates the key takeaways from GeneDx's Q4 2025 earnings call, highlighting both the company's achievements and the challenges it faces in a competitive landscape.